The full content will be available shortly. Thank you for your patience!
Cristian A. Hernández-Gaytán 1, Jorge Alcacio-Mendoza 1, Javier González-Chavira 1, Guillermo Feria-Bernal 1, Bernardo Gabilondo-Pliego 1, Ricardo Castillejos-Molina 1, Francisco Rodríguez-Covarrubias 1
1 Departamento de Urología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México
Cristian A. Hernández-Gaytán, Jorge Alcacio-Mendoza, Javier González-Chavira, Guillermo Feria-Bernal, Bernardo Gabilondo-Pliego, Ricardo Castillejos-Molina, Francisco Rodríguez-Covarrubias
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondence: Francisco Rodríguez-Covarrubias. Email: frodriguez.covarrubias@gmail.com
Objective: To compare treatment strategies and outcomes between high risk (HR) and very high-risk (VHR) patients initially treated with radical prostatectomy. Methods: This was a retrospective study of patients with HR and VHR prostate cancer patients initially treated with radical prostatectomy. We analyzed demographic and clinical variables. We performed Kaplan- Meier test to compare oncological outcomes. Results: There were a total of 112 patients (57 HR and 55 VHR patients). Median follow-up was 93 months. Postoperative prostate specific antigen was undetectable in 76.8% of HR and 51.8% of VHR patients. Moreover, VHR group received postoperative radiotherapy in 72.7% vs. 51.8% in the HR group (p = 0.03). Biochemical persistence was higher for VHR group (39.3% vs 19.6%; p = 0.03). Conclusions: We found a higher rate of postoperative RT and biochemical persistence in VHR group. These results are useful to counseling VHR patients for better estimating prognosis and decision making.
The full content will be available shortly. Thank you for your patience!
